MONITORING PRACTICE
Nutrition monitoring during major weight reduction
Nutritional monitoring is relevant during substantial pharmacologically driven weight loss. When intake falls quickly and stays low, the question is no longer only how much weight is being lost, but what the remaining diet still supplies — protein, micronutrients, fluid — and what the body is doing with it. This page summarises the monitoring frame the current literature supports. It is research context, not medical advice; individual monitoring decisions belong with a qualified clinician.
What the literature says to watch
The 2026 EASO/EFAD/ECPO consensus statement ↗ names protein targets, resistance exercise and explicit micronutrient-risk monitoring during rapid weight loss on incretin therapies. What it supports: monitoring is a society-level standard of research attention. What it does not prove: a specific panel, threshold or supplementation protocol — the statement frames categories of attention, not prescriptions.
The sarcopenia and sarcopenic-obesity scoping review ↗ adds the at-risk phenotype — older adults — and the cited countermeasure range of 1.2–1.6 g/kg/day protein plus resistance training, while noting the underlying evidence on muscle quantity, quality and physical performance is limited and inconsistent.
Composition itself needs direct measurement: DXA where available, read with the caveat that DXA lean mass includes water and non-muscle lean tissue ↗. Function — grip strength, performance measures — is the endpoint the 35-trial systematic review ↗ found absent from the incretin record; the single-arm SEMALEAN study ↗ shows what measuring it can add.
Symptoms, rate and reserves
Gastrointestinal symptoms matter nutritionally, not only for comfort: severe restriction of food intake and prolonged vomiting can contribute to thiamine deficiency, and humans maintain limited thiamine reserves. Rate of weight reduction is itself a monitoring variable — faster loss narrows the margin for nutritional error.
The RetaBone research interest is whether formulation architecture can be part of the monitoring answer — a weekly administration event that carries a thiamine component is a testable hypothesis, described under thiamine, muscle energy and nervous-system function and metabolic resilience. It is not a replacement for dietary adequacy, and this site makes no such claim.